Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aclaris Therapeutics (ACRS) Shares Outstanding (Diluted Average) (2019 - 2025)

Aclaris Therapeutics has reported Shares Outstanding (Diluted Average) over the past 7 years, most recently at $122.6 million for Q4 2025.

  • Quarterly results put Shares Outstanding (Diluted Average) at $122.6 million for Q4 2025, up 58.56% from a year ago — trailing twelve months through Dec 2025 was $122.6 million (up 58.56% YoY), and the annual figure for FY2025 was $122.6 million, up 58.56%.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $122.6 million at Aclaris Therapeutics, roughly flat from $122.6 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for ACRS hit a ceiling of $122.6 million in Q3 2025 and a floor of $50.3 million in Q1 2021.
  • Median Shares Outstanding (Diluted Average) over the past 5 years was $70.2 million (2023), compared with a mean of $77.0 million.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): grew 0.62% in 2024 and later skyrocketed 72.21% in 2025.
  • Aclaris Therapeutics' Shares Outstanding (Diluted Average) stood at $56.7 million in 2021, then increased by 14.95% to $65.2 million in 2022, then rose by 7.05% to $69.8 million in 2023, then rose by 10.73% to $77.3 million in 2024, then soared by 58.56% to $122.6 million in 2025.
  • The last three reported values for Shares Outstanding (Diluted Average) were $122.6 million (Q4 2025), $122.6 million (Q3 2025), and $122.6 million (Q2 2025) per Business Quant data.